2022
Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respiratory Research 2022, 9: e001254. PMID: 35882424, PMCID: PMC9329732, DOI: 10.1136/bmjresp-2022-001254.Peer-Reviewed Original ResearchMeSH KeywordsCommunicable DiseasesCOVID-19HumansPandemicsProspective StudiesQuality of LifeSARS-CoV-2Treatment OutcomeConceptsLung functionRespiratory infectionsLocal institutional review board approvalFibrotic pulmonary sarcoidosisInstitutional review board approvalNon-infected patientsInterstitial lung diseaseRespiratory viral illnessReview board approvalViral infectious diseasesImpact of infectionPulmonary sarcoidosisViral illnessClinical courseInfectious eventsStudy entryStudy cohortPoor outcomeProspective studyLung diseaseLong-term impactLife measuresSarcoidosisHigh riskGeneral population
2017
Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report
Ryu C, Herzog EL, Pan H, Homer R, Gulati M. Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report. American Journal Of Case Reports 2017, 18: 157-159. PMID: 28190872, PMCID: PMC5319306, DOI: 10.12659/ajcr.902231.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUpper airway obstructionRare extrapulmonary manifestationLaryngeal sarcoidosisLife-threatening complicationsAirway obstructionEmergent tracheostomyExtrapulmonary manifestationsCase reportComplete upper airway obstructionLow-dose prednisoneMonths of corticosteroidsStage 1 sarcoidosisAddition of methotrexateAfrican American femalesTapered dosageRespiratory failureSevere dyspneaInspiratory stridorSignificant morbidityPhysical examinationChronic careAryepiglottic foldsTimely diagnosisSarcoidosisPrednisone